Ovarian Cancer
Access Pharmaceuticals announces dosing of ProLindac in first patient in phase II trial
Published in Women's Health Weekly, July 6th, 2006
The study is being conducted in Europe, in ovarian cancer patients that have relapsed after first line platinum therapy. The first patient was dosed with the study medication in France. The open-label trial is being managed by Cvitkovic and Associates (CAC), a clinical research organization (CRO) with a specialty in platinum drugs, and will accrue approximately 40 patients.
"In our phase I trial, there were two responses in ovarian patients who had relapsed after prior cis- or...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Arthritis
Decline in physical functioning for women in midlife may begin earlier than expected - Cardiovascular Disease
Cardiac autonomic regulation may be positively affected by raloxifene - Cervical Cancer
Low podoplanin expression predicts poor prognosis in advanced-stage squamous cell carcinoma - HIV/AIDS Transmission
Single-dose nevirapine studies would enhance understanding of nevirapine-resistant HIV-1 - Uterine Cancer
Uterine serous papillary cancer may be diagnosed by elevated serum kallikrein 10 - Autoimmune Disease
Anticardiolipin detection in infants best assay to evaluate disappearance of maternal aPL - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
